Monday - December 23, 2024
American Society of Hematology: Adding Tafasitamab Cuts Risk of Disease Progression
December 11, 2024
WASHINGTON, Dec. 11 (TNSres) -- The American Society of Hematology issued the following news release:

* * *

Patients on tafasitamab had a 57% improvement in progression-free survival compared to the control arm

LBA-1: Tafasitamab Plus Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma: Results from a Phase III Study (inMIND)

* * *

(SAN DIEGO--Dec. 10, 2024) - Patients with follicular lymphoma that did not res . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products